New stock first day | "First Stock of Innovative Drug for Kidney Disease" Libang Medicine (09637) Listed for the first time, surging nearly 97% in the early trading session.

Lifton Pharmaceutical-B (09637) made its debut on the stock market. The announcement shows that the price was set at 22.6 Hong Kong dollars per share, with a total of 56.7554 million shares issued, each lot consisting of 100 shares, resulting in a net amount of approximately 1.181 billion Hong Kong dollars. As of the time of writing, the stock has risen by 95.22%, trading at 44.12 Hong Kong dollars, with a trading volume of 324 million Hong Kong dollars. According to public information, Lifton Pharmaceutical is a biopharmaceutical company that provides therapy for kidney diseases. Based on data from Zhaoshi Consulting, the company has the broadest range of candidate drugs for global kidney indications. As of the latest feasible date, the company's clinical and preclinical product portfolio consists of a core product, AP301, and six other candidate products, including a late-stage candidate product (AP306), an early-stage candidate drug (AP303), and four preclinical candidate drugs (AP308, AP304, AP305, and AP307). The core product, AP301 (obtained all global rights from Vidasym in 2021), has been classified as a new drug in China. AP301 is a phosphate binder used to treat hyperphosphatemia. Hyperphosphatemia is one of the most common complications in CKD patients undergoing dialysis, with a significant unmet medical need. AP301 has completed Phase III registration clinical trials in China and is expected to submit a New Drug Application (NDA) in the near future. Currently, global Phase III pivotal multicenter clinical trials are being conducted in the United States and China.